Tom 15, Nr 6 (2020)
Artykuł przeglądowy
Opublikowany online: 2020-12-31
Wyświetlenia strony
1028
Wyświetlenia/pobrania artykułu
518
Niewydolność serca z zachowaną frakcją wyrzutową — wyzwanie dla współczesnej kardiologii
DOI: 10.5603/FC.2020.0060
Folia Cardiologica 2020;15(6):407-412.
Streszczenie
Niewydolność serca z zachowaną frakcją wyrzutową (HFpEF) to heterogenna jednostka chorobowa, u podłoża rozwoju której jest wiele różnorodnych mechanizmów. Szacuje się, że ponad połowę przypadków niewydolności serca stanowi HFpEF, a w związku ze starzeniem się społeczeństwa liczba chorych będzie się zwiększała. W poniższym artykule przedstawiono aktualny stan wiedzy dotyczącej HFpEF.
Słowa kluczowe: niewydolność serca z zachowaną frakcją wyrzutowąHFpEF
Referencje
- Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020; 22(3): 391–412.
- Hancock HC, Close H, Mason JM, et al. High prevalence of undetected heart failure in long-term care residents: findings from the Heart Failure in Care Homes (HFinCH) study. Eur J Heart Fail. 2013; 15(2): 158–165.
- Ponikowski P, Voors AA, Anker SD, et al. [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. Kardiol Pol. 2016; 74(10): 1037–1147.
- Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018; 138(9): 861–870.
- Lam CSP, Voors AA, de Boer RA, et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018; 39(30): 2780–2792.
- Fonarow GC, Stough WG, Abraham WT, et al. OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50(8): 768–777.
- Sartipy U, Savarese G, Dahlström U, et al. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. Eur J Heart Fail. 2019; 21(4): 471–479.
- Ferrari R, Böhm M, Cleland JGF, et al. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail. 2015; 17(7): 665–671.
- Wintrich J, Kindermann I, Ukena C, et al. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin Res Cardiol. 2020; 109(9): 1079–1098.
- Zakeri R, Chamberlain AM, Roger VL, et al. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation. 2013; 128(10): 1085–1093.
- Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015; 131(1): 34–42.
- Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136(6): e137–e161.
- Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21(10): 1169–1186.
- Solomon SD, McMurray JJV, Anand IS, et al. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019; 381(17): 1609–1620.
- Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020; 141(5): 352–361.
- Bozkurt B, Ezekowitz J. Substance and substrate: LVEF and sex subgroup analyses of PARAGON-HF and PARADIGM-HF trials. Circulation. 2020; 141(5): 362–366.
- Xanthopoulos A, Triposkiadis F, Starling RC. Heart failure with preserved ejection fraction: classification based upon phenotype is essential for diagnosis and treatment. Trends Cardiovasc Med. 2018; 28(6): 392–400.
- Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019; 124(11): 1598–1617.
- Gard E, Nanayakkara S, Kaye D, et al. Management of heart failure with preserved ejection fraction. Aust Prescr. 2020; 43(1): 12–17.
